Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.

View in: PubMed

collapse authors with profiles